Applied Therapeutics, Inc. (APLT)
| Market Cap | 373.30M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -103.54M |
| Shares Out | 26.08M |
| EPS (ttm) | -4.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155,777 |
| Open | 14.44 |
| Previous Close | 14.36 |
| Day's Range | 14.04 - 14.76 |
| 52-Week Range | 13.58 - 29.80 |
| Beta | 1.13 |
| Analysts | Strong Buy |
| Price Target | 42.83 (+200.4%) |
| Est. Earnings Date | Nov 11, 2021 |
About APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for APLT stock is "Strong Buy." The 12-month stock price forecast is 42.83, which is an increase of 200.35% from the latest price.
News
Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead Candidate
Applied Therapeutics Inc (NASDAQ: APLT) has reported initial biomarker data from the pediatric ACTION-Galactosemia Kids study and baseline analysis of the 47 children enrolled in the study. Related Cont...
Applied Therapeutics Reports Second Quarter 2021 Financial Results
NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing
Applied Therapeutics Added to Russell Microcap® Index
NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientif...
~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the heart's ability to function People with diabetes or pre-diabetes who have D...
Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions ...
NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics Stock Moves Higher On FDA Fast Track Review For AT-007 In Rare Metabolic Disorder
The FDA has granted Fast Track designation to Applied Therapeutics Inc's (NASDAQ: APLT) AT-007 to treat Galactosemia, a rare metabolic disease. AT-007 is the Company's central nervous system-penetrant A...
Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference
NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecula...
Applied Therapeutics Reports First Quarter 2021 Financial Results
Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency
Applied Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA
Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics, Inc. Announces Closing of Public Offering
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...
Applied Therapeutics Raises $69M Via Equity
Applied Therapeutics Inc (NASDAQ: APLT) prices its underwritten public offering of 3 million at $23 per share, raising $69 million in gross proceeds, at a marginal premium of 2%. Underwriters have an op...
Applied Therapeutics, Inc. Announces Pricing of Public Offering of 3,000,000 Shares of Common Stock
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...
Applied Therapeutics, Inc. Announces Offering of 3,000,000 Shares of Common Stock
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...
Applied Therapeutics Announces Restart of Pediatric Galactosemia Study
FDA Clinical Hold Lifted
Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study
NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics Reports Third Quarter 2020 Financial Results
Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics)
Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopat...
Treatment with AT-001 normalizes cardiac energetics and improves cardiac function in a mouse model of Diabetic Cardiomyopathy (DbCM) Treatment with AT-001 normalizes cardiac energetics and improves card...
Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Gen...
NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...
Applied Therapeutics Inc. (APLT) Stock Sinks As Market Gains: What You Should Know
Applied Therapeutics Inc. (APLT) closed at $22.86 in the latest trading session, marking a -0.95% move from the prior day.
Could Applied Therapeutics Stock Rise 300%?
Applied Therapeutics Inc. (NASDAQ: APLT) shares pushed higher on Thursday after a new analyst report came out supposing massive upside for this biotech.
Applied Therapeutics Inc. (APLT) Gains As Market Dips: What You Should Know
Applied Therapeutics Inc. (APLT) closed at $20.02 in the latest trading session, marking a +0.05% move from the prior day.